New Haven, Connecticut, August 27, 2026, 10:20 (EDT) – Biohaven shares fell 7.1%, retracing nearly half of the gains made after its $400 million deal for Opakalim, with 47% of the post-announcement surge given back in trading.
- At 10:19 EDT, Biohaven shares dropped 7.1% to $15.75, reversing 47% of their $2.57 advance from Wednesday.
- The stock is still trading 9.5% higher than its closing level on August 25, ahead of the announcement of the epilepsy-platform agreement.
- Biohaven is set to obtain $350 million upon closing, with an additional $50 million to follow after one year.
- Wednesday saw a volume of 15.77 million shares, which was 5.2 times higher than its 65-day average.
Shares of Biohaven Ltd. NYSE:BHVN dropped 7.1% on Thursday, with investors re-evaluating the financial terms of its opakalim licensing deal. The stock was at $15.75 at 10:19 EDT, a decline of $1.20.
The pullback wiped out 47% of Wednesday’s $2.57 increase. Biohaven remained 9.5% higher than its $14.38 close before the deal. This mixed response reflects the value of the cash injection while overlooking the forfeited commercial potential.
Biohaven climbed 17.9% on Wednesday, trading 15.77 million shares—5.2 times its 65-day average. By 10:19 EDT Thursday, volume was 962,594 shares price and volume data.
Under the terms, SK Biopharmaceuticals will make an upfront payment of $400 million. Biohaven will get $350 million upon closing, followed by a $50 million payment after one year. The initial payment represents 14.7% of Biohaven’s approximate $2.38 billion quoted valuation.
| Deal component | Amount | Share of current market value | Condition |
|---|---|---|---|
| Cash paid at closing | $350 million | 14.7% | Subject to antitrust approval and typical conditions |
| Cash paid after one year | $50 million | 2.1% | Following completion |
| Payments for development and regulatory milestones | Up to $150 million | 6.3% | Upon meeting outlined goals |
| Obligations assumed from Knopp | Up to $245 million | 10.3% | To be paid by SK after deal closure |
| Aggregate Kv7-associated payments | Up to $795 million | 33.4% | Comprises contingent payments |
Biohaven’s cash, securities, and restricted cash amounted to $270.5 million as of June 30. The $400 million in near-term consideration is equivalent to 1.48 times that liquidity figure second-quarter results.
The agreement grants an exclusive global license for Biohaven’s Kv7 platform. The main asset, opakalim, is currently undergoing Phase 2/3 trials targeting focal epilepsy. Topline results from the RISE3 study are anticipated in the second half of 2026.
SK is set to take on up to $245 million in certain milestone obligations from Knopp Biosciences. Biohaven will keep royalty rates ranging from the mid-teens to the low twenties on opakalim sales within the U.S. Royalties outside the U.S. will be in the mid-single digits August 26 SEC filing.
The arrangement eases Biohaven’s financial obligations. SK will cover designated development plan expenses and repay particular pre-closing costs. Biohaven is required to proceed with the RISE2 and RISE3 trials and ready the drug submission.
The trade-off involves losing future control. Leonid Timashev, an analyst at RBC Capital Markets, described the deal as “fairly surprising,” noting that opakalim represented Biohaven’s most advanced asset. The timing, coming just ahead of key data, could account for Thursday’s reversal BioPharma Dive.
Wall Street sentiment is upbeat yet split over valuation. Out of analysts, eleven recommend Buy and one has marked Overweight; three suggest Hold and one Underweight. The average target stands at $22.07, indicating a potential upside of 40.1%, while the lowest target of $10 suggests 36.5% downside.
Risks are binary. The deal’s completion depends on antitrust approval, with SK holding the option to terminate at its discretion afterward. Milestone payments and royalties are linked to progress in clinical trials, regulatory approval, and sales; poor RISE3 results could eliminate the most significant contingent value in the agreement.
The upcoming measurable test is RISE3. In the meantime, the share price reflects an extended cash runway, weighed against reduced direct ownership of Biohaven’s leading drug candidate.
Related articles: Pharmaceuticals
